摘要
目的:观察罗沙司他联合右旋糖酐铁治疗非透析依赖性慢性肾脏病肾性贫血患者的效果。方法:回顾性分析2020年6月至2023年4月该院收治的198例非透析依赖性慢性肾脏病肾性贫血患者的临床资料,按照治疗方法不同将其分为对照组和观察组各99例。对照组采用右旋糖酐铁治疗,观察组在对照组基础上联合罗沙司他治疗,两组均连续治疗12周。比较两组临床疗效,治疗前后血常规指标[血红蛋白(Hb)、红细胞计数(RBC)]水平、血清铁蛋白(SF)水平、炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)]水平,以及不良反应发生率。结果:观察组治疗总有效率为95.96%(95/99),高于对照组的84.85%(84/99),差异有统计学意义(P<0.05);治疗后,观察组Hb、RBC、SF水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组CRP、IL-6水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:罗沙司他联合右旋糖酐铁治疗非透析依赖性慢性肾脏病肾性贫血患者可提高治疗总有效率、血常规指标水平和SF水平,降低炎性因子水平,效果优于单纯右旋糖酐铁治疗。
Objective:To observe effects of Roxadustat combined with Iron dextran in treatment of renal anemia patients with non-dialysis-dependent chronic kidney disease.Methods:The clinical data of 198 renal anemia patients with non-dialysis-dependent chronic kidney disease admitted to this hospital from June 2020 to April 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,99 cases in each group.The control group was treated with Iron dextran,while the observation group was treated with Roxadustat on the basis of that of the control group.Both groups were treated continuously for 12 weeks.The clinical efficacy,the blood routine indexes[hemoglobin(Hb),red blood cell count(RBC)]levels,serum ferritin(SF)level,the inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.96%(95/99),which was higher than 84.85%(84/99)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of Hb,RBC and SF in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP and IL-6 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Roxadustat combined with Iron dextran in the treatment of the renal anemia patients with non-dialysis-dependent chronic kidney disease can improve the total effective rate of treatment,the levels of blood routine indexes and the level of SF,and reduce the levels of inflammatory factors.Moreover,it is superior to single Iron dextran treatment.
作者
李晗
LI Han(Department of Nephrology of the First Affiliated Hospital of Nanyang Medical College,Nanyang 473000 Henan,China)
出处
《中国民康医学》
2024年第1期39-41,共3页
Medical Journal of Chinese People’s Health
关键词
非透析依赖性
慢性肾脏病
肾性贫血
右旋糖酐铁
罗沙司他
血常规
炎性因子
Non-dialysis dependence
Chronic kidney disease
Renal anemia
Iron dextran
Roxadustat
Blood routine
Inflammatory factor
作者简介
李晗(1985.07-),女,汉族,河南南阳人,本科,主治医师,研究方向为肾性贫血、慢性肾脏病、肾病综合征等。
